ALTO vs HDSN

ALTO's deterministic health scores reveal significant concerns: a Piotroski F-Score of 2/9 indicates weak financial health, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the stock trades at a discount to its Graham Number ($3.38) and intrinsic value ($1.12), suggesting potential undervaluation. The recent earnings surprise history is volatile but highly positive in the most recent quarters, with a 75% Q/Q EPS growth and 149% YoY EPS growth. Strong price momentum—253% 1-year return and 294.9% 6-month return—reflects market optimism, supported by a strong-buy analyst consensus. However, the company's negative revenue growth (-1.90% YoY) and minimal profitability (1.45% profit margin) remain critical red flags. Price trades at a 37.9% premium to fair value estimate ($3.38), limiting near-term upside from a valuation perspective.

HDSN exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY EPS decline of 116.7%. While the company maintains a clean balance sheet with very low debt (D/E 0.02) and trades below its Graham Number ($6.98), the divergence between strong revenue growth (28.2%) and negative operating margins (-16.23%) suggests an unsustainable operational model. Insider selling and a bearish technical trend further undermine the optimistic analyst target of $9.00.